CSIMarket


Biomarin Pharmaceutical Inc  (NASDAQ: BMRN)
Other Ticker:  
 

Biomarin Pharmaceutical Inc

BMRN's Fundamental analysis








Looking into Biomarin Pharmaceutical Inc growth rates, revenue grew by 28.28 % in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 1378

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %

Biomarin Pharmaceutical Inc's net income grew by 162.72 % in III. Quarter 2024 year on year, above company average,

More on BMRN's Growth


Biomarin Pharmaceutical Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Biomarin Pharmaceutical Inc PEG ratio is at 0.33 Biomarin Pharmaceutical Inc realized cash reduction of $ -0.56 per share in trailing twelve-month period.
Company
38.36
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.58.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.


More on BMRN's Valuation
 
 Total Debt (Millions $) 595
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 809,412
 Net Income/Employee (TTM) $ 94,764
 Receivable Turnover (TTM) 4.02
 Tangible Book Value (Per Share $) 25.14

Biomarin Pharmaceutical Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Biomarin Pharmaceutical Inc PEG ratio is at 0.33 Biomarin Pharmaceutical Inc realized cash outflow of $ -0.56per share in trailing twelve-month period.
Company
38.36
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 4.58.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.17.

Biomarin Pharmaceutical Inc Price to Book Ratio is at 2.33 lower than Industry Avg. of 89.07. and higher than S&P 500 Avg. of 0.01

More on BMRN's Valuation

  Market Capitalization (Millions $) 12,604
  Shares Outstanding (Millions) 197
  Employees 3,401
  Revenues (TTM) (Millions $) 2,753
  Net Income (TTM) (Millions $) 322
  Cash Flow (TTM) (Millions $) -110
  Capital Exp. (TTM) (Millions $) -114
  Total Debt (Millions $) 595
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 809,412
  Net Income/Employee(TTM) $ 94,764
  Receivable Turnover Ratio (TTM) 4.02
  Tangible Book Value (Per Share $) 25.14

  Market Capitalization (Millions $) 12,604
  Shares Outstanding (Millions) 197
  Employees 3,401
  Revenues (TTM) (Millions $) 2,753
  Net Income (TTM) (Millions $) 322
  Cash Flow (TTM) (Millions $) -110
  Capital Exp. (TTM) (Millions $) -114


    BMRN's Profitability Comparisons
Biomarin Pharmaceutical Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 15.27 % from 16.92 % in II. Quarter.

Biomarin Pharmaceutical Inc net profit margin of 14.22 % is currently ranking no. 37 in Major Pharmaceutical Preparations industry, ranking no. 83 in Healthcare sector and number 1012 in S&P 500.


Profitability by Segment
Total 14.22 %



  Ratio
   Capital Ratio (MRQ) 4.27
  Total Debt to Equity (MRQ) 0.11
  Tangible Leverage Ratio (MRQ) 0.29
  Asset Turnover Ratio (TTM) 0.4
  Inventory Turnover Ratio (TTM) 0.5



Biomarin Pharmaceutical Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in III. Quarter 2024 to 15.27 % from 16.92 % in II. Quarter.

Biomarin Pharmaceutical Inc net profit margin of 14.22 % is currently ranking no. 37 in Major Pharmaceutical Preparations industry, ranking no. 83 in Healthcare sector and number 1012 in S&P 500.

More on BMRN's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com